JOHN DELLOSSO: Open Payments
NPI 1942299920 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,939 in 207 payments from 24 companies in 2025. Trend: 2023 $3,851 · 2024 $3,504 · 2025 $3,939
Food & beverage: $3,939
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 44 | $820 |
| Gilead Sciences, Inc. | 38 | $702 |
| ABBVIE INC. | 30 | $538 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $244 |
| Axsome Therapeutics, Inc. | 11 | $205 |
| Lundbeck LLC | 10 | $166 |
| EMD Serono, Inc. | 11 | $142 |
| AstraZeneca Pharmaceuticals LP | 6 | $137 |
| Otsuka America Pharmaceutical, Inc. | 9 | $136 |
| Abbott Laboratories | 1 | $126 |
Products named: DOVATO, APRETUDE, REXULTI, CAPLYTA, MAVYRET, Auvelity, VRAYLAR, SWIFT-LOCK.
Industry payments across NY — which companies pay providers there.
